Navigation Links
AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
Date:3/20/2008

Physicians Indicate that Most Promising Emerging Therapies Will Not Match the Current Gold-Standard Avastin/Taxol/Paraplatin Regimen's Efficacy,

According to a New Report from Decision Resources

WALTHAM, Mass., March 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the emerging drug Zactima from AstraZeneca will earn 4.7 percent patient share in the treatment of non-small-cell lung cancer (NSCLC) by 2016. Surveyed oncologists indicate that they would prescribe Zactima to 30 percent of their patients with advanced non-small-cell lung cancer. Also, 38 percent of the physicians surveyed indicate they will use Zactima as an adjunct to current therapy rather than as a replacement. Zactima is forecasted to launch in 2008 in the United States and Europe and in 2010 in Japan.

According to the new report entitled Non-Small-Cell Lung Cancer (Advanced): Current Gold-Standard Therapy Continues to Be Most Efficacious; physicians indicate that the most promising emerging therapies for the treatment of non-small-cell lung cancer will not match the current gold- standard regimen comprising Roche/Genentech/Chugai's Avastin, Bristol-Myers Squibb's Taxol, and Bristol-Myers Squibb's Paraplatin.

"Although some therapies in development for advanced NSCLC hold promise, most have efficacy, safety and tolerability, and/or delivery features that merit inferior scores compared with the Avastin/Taxol/Paraplatin regimen," said Andrew Merron, Ph.D., analyst at Decision Resources. "A therapy's effect on overall survival is the attribute that most influences prescribing decisions in advanced non-small-cell lung cancer. Data and the opinions of interviewed thought leaders indicate that Avastin/Taxol/Paraplatin has advantages over the sales-leading combination of Sanofi-Aventis's Taxotere and Bristol-Myers Squibb's Platinol-AQ on overall survival."

About
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
2. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
3. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
4. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
5. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
6. LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems
7. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
8. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
9. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
10. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
11. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...KING OF PRUSSIA, Pa., Nov. 30 Cad...alizing in interactive marketing services and sol...d the launch of its HATCH Consulting service...gning strategic experts across a range of emerging... Consulting team is committed to guiding companies...
(Date:11/30/2009)...K, Nov. 30 The Michael ...today announced $1.5 million in total awards to si...sease-modifying therapies for Parkinson,s disease....es to Drug Discovery for Parkinson,s Disease prog...n, plc (NYSE: ELN ), a neuroscience-based biotec...
(Date:11/30/2009)...IARCLIFF MANOR, N.Y., Nov. 30 Good...ument for the publication of company-sponsored med...the British Medical Journal (BMJ). "The publicatio...rtance of providing support and guidance for indus...y results in the peer-reviewed medical literature,...
(Date:11/30/2009)...Nov. 30 Dr. Jessica Torrente, Assi...University Medical Center in Washington, D.C., dem...ic Gamma Imaging (BSGI) in clinical practice as an...ast cancer today at the annual meeting of the Radi...he purpose of the exhibit was to demonstrate how B...
Breaking Biology Technology:Cadient Interactive Announces the Launch of HATCH Consulting Services 2Cadient Interactive Announces the Launch of HATCH Consulting Services 3The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2
...dings, Inc. (OTC,Bulletin Board: HTWO) today annou... Financial Officer, effective December 1, 2007., ...cial Officer of,Osiris Therapeutics, Inc. where he...ogy organizations and served as a strategic busine...rom 2001 to 2004, Mr.,Claiborne was the Vice Presi...
....6 Million for Q3 of 2007 versus $5.2 Million ...rofit increases 102% to $2.6 Million for Q3 of 200...Q3 of 2006 -- Announces Restructuring of $12.5...hua-PRNewswire/ -- China Biopharmaceuticals,Holdin...nese pharmaceutical,company focused on the develop...
... Inc. (Amex: ADL,- News), headquartered in Tustin,...nd Jilin, China, through its wholly owned subsidia...onal biopharma company that,engages in the develop...rmaceutical and diagnostic products. The Company a... CEO, Gary Dreher, at the prestigious 9th,Annual H...
Other Biology Technology:H2Diesel Announces Appointment of Cary J. Claiborne as Chief Financial Officer 2H2Diesel Announces Appointment of Cary J. Claiborne as Chief Financial Officer 3China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 2China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 3China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 4China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 5China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 6China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 7AMDL Presentation of China Success Story from Rodman & Renshaw Annual Healthcare Conference Available at WallStreetReporter.com 2
(Date:12/1/2009)...ust for listening to the radio anymore. They,re us...Research from North Carolina State University is r...ng shape-shifting antennas that open the door to a...fety to military deployment. , Modern antennas a... limitations to how far they can be bent and how ...
(Date:11/30/2009)...ganisation is needed to monitor the commitments th...gen to cut their deforestation rates, according to... government agencies and research groups have fail...images of the Earth,s surface collected each week ...blished by Dr Alan Grainger in the Proceedings of...
(Date:11/30/2009)...s of gravy and dessert at the holiday table are ev...y thought. According to a new research report rece...p://www.fasebj.org ), a diet that is high in fat a...tely cause our bodies to store too much fat. This ...the already difficult task of converting high-fat ...
Breaking Biology News(10 mins):Shape shifters: Researchers create new breed of antennas 2World forest observatory needed to monitor vital role of forests in climate deal 2Happy holidays from the groaning board; Western diets turn on fat genes 2University of Maryland Company Trauma Solutions Named Finalist in 24250K Draper Fisher Jurvetson and Cisco Systems Global Business Plan Competition 50088 1University of Maryland Company Trauma Solutions Named Finalist in 24250K Draper Fisher Jurvetson and Cisco Systems Global Business Plan Competition 50088 2University of Maryland Company Trauma Solutions Named Finalist in 24250K Draper Fisher Jurvetson and Cisco Systems Global Business Plan Competition 50088 3Abused Kids Face Higher Cancer Risk 50083 1Abused Kids Face Higher Cancer Risk 50083 2The AGA Foundation awards grant to Dr Michael Choi to further his research on carcinoid tumors 50078 1The AGA Foundation awards grant to Dr Michael Choi to further his research on carcinoid tumors 50078 2
...,green, can potentially contain a naturally occurr...sk to public health according to a review paper pu...al of the Science of Food and Agriculture (JSFA)....e ,green, affected area is enough to eliminate mos...o suggests that the levels of GA in potatoes can b...
...lescope promise to make it easier for people with ...equiring sharper distance vision. Schepens Eye Res... of these innovative glasses over earlier devices ...Journal of Biomedical Optics , mailed in print fo... has several advantages," says the inventor of the...
... In the life of a cell, the response to DNA damage... repair itself, commit suicide, or grow uncontroll...ublished in the July 25th issue of Cell , scienti...a way that cells respond to DNA damage through a p...ding points to a new pathway for the development o...
Other Biology News:Telescope embedded in glasses lens promises to make driving easier for visually impaired 2Telescope embedded in glasses lens promises to make driving easier for visually impaired 3A new cellular pathway linked to cancer is identified by NYU researchers 2
Mouse Anti-Rat GM130 Monoclonal Antibody, Unconjugated, Clone NN 2C10/1 from ABR-Affinity BioReagents
Rat OSTEOCALCIN Native from AbD Serotec
... 15/16" x 5 5/16"18.7 lbsCapacity: 12 slidesTime:...0 - 99C Automated denaturation and hybridization s...des (Denaturation/Hybridization, Hybridization onl...p from 37 - 95C and cooling from 79 - 37C Uniform ...
Rabbit Anti-Defender against cell death 1 Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
Biology Products: